Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S100A4 | P26447 | 2/20 | 0.39 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | CDC25B | P30305 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.35 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 4/20 | 0.34 |
| ▸ | MAPT | P10636 | 4/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | RAB9A | P51151 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | PTPRC | P08575 | 2/20 | 0.34 |
| ▸ | BLM | P54132 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.34 |
| ▸ | APAF1 | O14727 | 2/20 | 0.34 |
| ▸ | CES2 | O00748 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29854261 | 0.71 | TRPA1 (0.41) | — | |
| SCHEMBL8276 | 0.71 | TRPA1 (0.41) | — | |
| Hydrochloric Acid SCHEMBL10718555 | 0.69 | TRPA1 (0.39) | MEN1KMT2AALDH1A1 | |
| SCHEMBL5139730 | 0.68 | CDC25B (0.46) | S100A4MEN1KMT2ACDC25BALDH1A1 | |
| SCHEMBL3540607 | 0.68 | S100A4 (0.52) | S100A4MEN1KMT2ACDC25BALDH1A1 | |
| SCHEMBL1354170 | 0.66 | KDM4E (0.41) | S100A4MEN1KMT2ACDC25BALDH1A1 | |
| SCHEMBL57213 | 0.65 | CA12 (0.42) | MEN1KMT2ACDC25BTDP2BCHE | |
| SCHEMBL29824315 | 0.65 | CA12 (0.42) | MEN1KMT2ACDC25BTDP2BCHE | |
| SCHEMBL29698819 | 0.64 | HPGD (0.48) | S100A4ADAMTS5MEN1KMT2ACDC25B | |
| SCHEMBL69404 | 0.64 | HPGD (0.48) | S100A4ADAMTS5MEN1KMT2ACDC25B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9770520-B2 | Chelate nanoemulsion for MRI | GUERBET (FR) | 2017-09-26 | — | — | US | disclosed |
| EP-2576536-B1 | HAEMATOPOIETIC-PROSTAGLANDIN D2 SYNTHASE INHIBITORS | UNIV QUEENSLAND (AU) | 2016-09-14 | — | — | EP | disclosed |
| US-9199976-B2 | Haematopoietic-prostaglandin D2 synthase inhibitors | THE UNIVERSITY OF QUEENSLAND (AU) | 2015-12-01 | — | — | US | disclosed |
| US-20150320889-A1 | Vectorised Magnetic Emulsion | GUERBET (FR) | 2015-11-12 | — | — | US | disclosed |
| US-20130309176-A1 | CHELATE NANOEMULSION FOR MRI | UNIVERSITE DE BORDEAUX 1 (FR) | 2013-11-21 | — | — | US | disclosed |
| US-20130137684-A1 | HAEMATOPOIETIC-PROSTAGLANDIN D2 SYNTHASE INHIBITORS | THE UNIVERSITY OF QUEENSLAND (AU) | 2013-05-30 | — | — | US | disclosed |
| EP-2576536-A2 | HAEMATOPOIETIC-PROSTAGLANDIN D2 SYNTHASE INHIBITORS | The University of Queensland (AU) | 2013-04-10 | — | — | EP | disclosed |
| WO-2011150457-A2 | HAEMATOPOIETIC-PROSTAGLANDIN D2 SYNTHASE INHIBITORS | THE UNIVERSITY OF QUEENSLAND (AU) | 2011-12-08 | — | — | WO | disclosed |
| WO-2005113573-A2 | METHOD OF SUPPORT-BASED CHEMICAL SYNTHESIS | MIXTURE SCIENCES, INC. (US) | 2005-12-01 | — | — | WO | disclosed |
| US-20050261474-A1 | Method of support-based chemical synthesis | MIXTURE SCIENCES, INC. | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137684-A1 | HAEMATOPOIETIC-PROSTAGLANDIN D2 SYNTHASE INHIBITORS | HPGDS, PTGES, PTGIS | S100A4 2065/4885ADAMTS5 1743/4885MEN1 4596/4885 |
| US-20130309176-A1 | CHELATE NANOEMULSION FOR MRI | SGMS1, SGMS2, PHOSPHO1 | S100A4 441/4885ADAMTS5 4266/4885MEN1 609/4885 |
| US-20150320889-A1 | Vectorised Magnetic Emulsion | SGMS2, TFRC, SGMS1 | S100A4 1169/4885ADAMTS5 4558/4885MEN1 1290/4885 |
| US-20050261474-A1 | Method of support-based chemical synthesis | CYP2F1, CYP4F3, CYP4F2 | S100A4 1751/4885ADAMTS5 3656/4885MEN1 932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.